Close

Prothena Corp. (PRTA) Halts Development of NEOD001 for AL Amyloidosis

April 23, 2018 8:00 AM EDT Send to a Friend
Prothena Corporation plc (Nasdaq: PRTA), a clinical stage biotechnology company focused on the discovery and development of novel therapies in ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login